Promising developments in targeted therapies for non-small-cell lung cancer

Desirée Hao, Manuel Hidalgo

Research output: Contribution to journalArticle

Abstract

Despite advances in chemotherapy, radiation therapy, and surgery, the overall survival for patients with lung cancer remains poor. Thus, novel therapeutic approaches are warranted. As knowledge of the molecular abnormalities and dysregulated cellular processes contributing to the pathogenesis and progression of lung cancer has been acquired, intense interest has been directed at developing agents that target these abnormalities. New agents targeting aberrant receptor tyrosine kinases, the Ras oncoprotein, mediators of metastases and angiogenesis, and the tumor suppressor gene p53 have, among other agents, shown promise in preclinical studies. Early clinical trials with these agents in patients with advanced malignancies suggest preliminary evidence of clinical activity and possible applications in non-small-cell lung cancer (NSCLC). Ongoing clinical trials will help clarify the settings in which these agents are of greatest therapeutic value, the optimal schedule of administration, toxicities associated with chronic administration, and hopefully, provide additional insight into the biology of lung cancer. Selected clinical trials will be presented to highlight the use of rationally designed, targeted therapies for patients with NSCLC.

Original languageEnglish (US)
Pages (from-to)111-123
Number of pages13
JournalClinical Lung Cancer
Volume4
Issue number2
StatePublished - Sep 2002
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Clinical Trials
Oncogene Proteins
Receptor Protein-Tyrosine Kinases
Proxy
Tumor Suppressor Genes
Appointments and Schedules
Radiotherapy
Therapeutics
Neoplasm Metastasis
Drug Therapy
Survival
Neoplasms

Keywords

  • Angiogenesis inhibitors
  • Clinical trials
  • Gene therapy
  • Matrix metalloproteinase inhibitors
  • Signal-transduction inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Promising developments in targeted therapies for non-small-cell lung cancer. / Hao, Desirée; Hidalgo, Manuel.

In: Clinical Lung Cancer, Vol. 4, No. 2, 09.2002, p. 111-123.

Research output: Contribution to journalArticle

Hao, Desirée ; Hidalgo, Manuel. / Promising developments in targeted therapies for non-small-cell lung cancer. In: Clinical Lung Cancer. 2002 ; Vol. 4, No. 2. pp. 111-123.
@article{798aaa577f6b4acfb1628a956eece842,
title = "Promising developments in targeted therapies for non-small-cell lung cancer",
abstract = "Despite advances in chemotherapy, radiation therapy, and surgery, the overall survival for patients with lung cancer remains poor. Thus, novel therapeutic approaches are warranted. As knowledge of the molecular abnormalities and dysregulated cellular processes contributing to the pathogenesis and progression of lung cancer has been acquired, intense interest has been directed at developing agents that target these abnormalities. New agents targeting aberrant receptor tyrosine kinases, the Ras oncoprotein, mediators of metastases and angiogenesis, and the tumor suppressor gene p53 have, among other agents, shown promise in preclinical studies. Early clinical trials with these agents in patients with advanced malignancies suggest preliminary evidence of clinical activity and possible applications in non-small-cell lung cancer (NSCLC). Ongoing clinical trials will help clarify the settings in which these agents are of greatest therapeutic value, the optimal schedule of administration, toxicities associated with chronic administration, and hopefully, provide additional insight into the biology of lung cancer. Selected clinical trials will be presented to highlight the use of rationally designed, targeted therapies for patients with NSCLC.",
keywords = "Angiogenesis inhibitors, Clinical trials, Gene therapy, Matrix metalloproteinase inhibitors, Signal-transduction inhibitors",
author = "Desir{\'e}e Hao and Manuel Hidalgo",
year = "2002",
month = "9",
language = "English (US)",
volume = "4",
pages = "111--123",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Promising developments in targeted therapies for non-small-cell lung cancer

AU - Hao, Desirée

AU - Hidalgo, Manuel

PY - 2002/9

Y1 - 2002/9

N2 - Despite advances in chemotherapy, radiation therapy, and surgery, the overall survival for patients with lung cancer remains poor. Thus, novel therapeutic approaches are warranted. As knowledge of the molecular abnormalities and dysregulated cellular processes contributing to the pathogenesis and progression of lung cancer has been acquired, intense interest has been directed at developing agents that target these abnormalities. New agents targeting aberrant receptor tyrosine kinases, the Ras oncoprotein, mediators of metastases and angiogenesis, and the tumor suppressor gene p53 have, among other agents, shown promise in preclinical studies. Early clinical trials with these agents in patients with advanced malignancies suggest preliminary evidence of clinical activity and possible applications in non-small-cell lung cancer (NSCLC). Ongoing clinical trials will help clarify the settings in which these agents are of greatest therapeutic value, the optimal schedule of administration, toxicities associated with chronic administration, and hopefully, provide additional insight into the biology of lung cancer. Selected clinical trials will be presented to highlight the use of rationally designed, targeted therapies for patients with NSCLC.

AB - Despite advances in chemotherapy, radiation therapy, and surgery, the overall survival for patients with lung cancer remains poor. Thus, novel therapeutic approaches are warranted. As knowledge of the molecular abnormalities and dysregulated cellular processes contributing to the pathogenesis and progression of lung cancer has been acquired, intense interest has been directed at developing agents that target these abnormalities. New agents targeting aberrant receptor tyrosine kinases, the Ras oncoprotein, mediators of metastases and angiogenesis, and the tumor suppressor gene p53 have, among other agents, shown promise in preclinical studies. Early clinical trials with these agents in patients with advanced malignancies suggest preliminary evidence of clinical activity and possible applications in non-small-cell lung cancer (NSCLC). Ongoing clinical trials will help clarify the settings in which these agents are of greatest therapeutic value, the optimal schedule of administration, toxicities associated with chronic administration, and hopefully, provide additional insight into the biology of lung cancer. Selected clinical trials will be presented to highlight the use of rationally designed, targeted therapies for patients with NSCLC.

KW - Angiogenesis inhibitors

KW - Clinical trials

KW - Gene therapy

KW - Matrix metalloproteinase inhibitors

KW - Signal-transduction inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0036750658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036750658&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 111

EP - 123

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -